Merus B.V.
Merus’ technologies are ideally suited to address multiple targets in a single therapeutic product. The key to the multispecific antibody therapeutics generated by Merus is a common light chain (cLC) shared by individual antibodies. With MeMo®, Oligoclonics® and Biclonics™, Merus has built a strong technology base to expand a pipeline of innovative cLC antibody products.
Merus discovers and develops innovative therapeutic human multispecific antibodies with improved clinical efficacy based on its common light chain (cLC) antibody technologies
